Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Ramakrishnan, Karthik
Mojebi, Ali
Ayers, Dieter
Chirovsky, Diana Romana
Borse, Rebekah
Keeping, Sam
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] PRECISIONheor, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18012
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
    Rischin, Danny
    Harrington, Kevin Joseph
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    Castro, Gilberto
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash C.
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett Gordon Maxwell
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Lin, Jianxin
    Gumuscu, Burak
    Swaby, Ramona F.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
    Tahara, M.
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Burtness, B.
    De Castro, G., Jr.
    Psyrri, A.
    Brana, I.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia Nin, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Gumuscu, B.
    Lerman, N.
    Soulieres, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S844 - S844
  • [23] Pembrolizumab (pembro) plus carboplatin (carbo) plus paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
    Dzienis, M. R.
    Cundom, J. E.
    Fuentes, C. S.
    Hansen, A. R.
    Nordlinger, M. J.
    Pastor, A. V.
    Oppelt, P.
    Neki, A.
    Gregg, R. W.
    Lima, I. P. F.
    Franke, F. A.
    Da Cunha Junior, G. F.
    Tseng, J. E.
    Loree, T.
    Joshi, A. J.
    Mccarthy, J. S.
    Naicker, N.
    Sidi, Y.
    Gumuscu, B.
    De Castro, G., Jr.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S839 - S840
  • [24] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [25] LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Siu, L. L.
    Burtness, B.
    Cohen, E. E.
    Harrington, K. J.
    Licitra, L. F.
    Rischin, D.
    Zhu, Y.
    Okpara, C. E.
    Pinheiro, C.
    Swaby, R. F.
    Machiels, J-P.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S684
  • [26] PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
    Ishak, W. Binti Wan
    Cheong, S.
    Nor, I. Muhamad
    Selvam, B.
    Ho, G.
    Tan, C.
    Wong, Y.
    Kue, P.
    Wai, A.
    Yahya, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1386 - S1386
  • [27] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
    Gui, L.
    Chen, X.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1609 - S1610
  • [28] Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Borcoman, Edith
    Marret, Gregoire
    Le Tourneau, Christophe
    CANCERS, 2021, 13 (11)
  • [29] Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma
    Weiss, Jared M.
    Bagley, Stephen
    Hwang, Wei-Ting
    Bauml, Joshua
    Olson, Juneko Grilley
    Cohen, Roger B.
    Hayes, David Neil
    Langer, Corey
    CANCER, 2016, 122 (15) : 2350 - 2355
  • [30] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA IN COLOMBIA
    Urrego-Reyes, J.
    Lopez, C.
    Marrugo, A. C.
    Wurcel, V
    Khandelwal, A.
    Patel, A.
    Black, C.
    VALUE IN HEALTH, 2023, 26 (06) : S95 - S95
12345